5WHO. World Malaria Report 2009[EB/OL]. http://www. who. int/malaria/world_malaria_report 2009/en/index. html.
6Glyde DF. Immunity to falctparum and vivax malaria induced by trradiated review of the university of Maryland studies, 1971 - 1975[M]. Bull WHO, 1990.9- 12.
7Ballou WR, Cahill CP. Two decades of commitment to malaria vaccine development : glaxosmithkline biologicals [J]. The American Society of Tropical Medicine and Hygiene, 2007,77(6) : 289- 95.
8Grtchen V. A complex mew vaccine shows promise[J]. Science, 2004,306..587-9.
9Jose AS, Gray D, Heppner JR. Phase 1 Safety and immunogenicity trial of malaria vaccine RTS,S/ASo2A in adults in a hyperendemic region of Western Kenya[J]. Am J Trop Med Hyg, 2006,75 (1):166-70.
10Cevayir C,Ken JI,Anthony WS.Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25,a Plasmodium falciparum transmission-blocking vaccine antigen[J].Infect Immu,2004,1:584-8.
